Trial Profile
A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CV MG01 (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; First in man; Pharmacodynamics; Proof of concept
- Sponsors CuraVac
- 25 Jan 2019 Status changed from active, no longer recruiting to completed.
- 26 Jan 2018 Planned End Date changed from 30 Nov 2017 to 30 Nov 2019.
- 26 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 12 Sep 2019.